Amgen 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter total revenues grew 8% year-over-year to 10.4 billion dollars, and product sales grew 8% year-over-year.
- Amgen’s six key growth drivers grew 27% year-over-year and represented over 70% of third-quarter product sales; 17 products delivered double-digit sales growth, and 17 products were annualizing at more than 1 billion dollars based on third-quarter sales.
- Repatha sales grew 37% year-over-year to 1.1 billion dollars; Evenity sales increased 13.9% to 751 million dollars; and TEZSPIRE sales grew 43% to 538 million dollars.
- The rare disease portfolio grew 21% year-over-year to 1.6 billion dollars; Uplezna sales increased 191% to 451 million dollars, while Tepezza sales declined 6% to 526 million dollars.
- The biosimilar portfolio grew 26% year-over-year to 977 million dollars, including PABBLU sales of 300 million dollars, up 41%. Innovative oncology grew 21% to 2.1 billion dollars; BLINCYTO sales increased 27% to 496 million dollars, and IMDELTRA sales more than doubled to 406 million dollars.
- Amgen reported positive Phase 3 results for IMDELTRA in small-cell lung cancer, TEZSPIRE in eosinophilic esophagitis, and dazodalibep in Sjögren's disease.
- Third-quarter non-GAAP operating margin was 47%; non-GAAP R&D spending increased 11% year-over-year, SG&A expenses decreased 1% year-on-year, and free cash flow was 3.7 billion dollars.
- Capital expenditures were 600 million in the quarter, and Amgen returned capital through dividend payments of $2.52 per share, a 6% increase compared with the third quarter of 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
My name is Julianne, and I will be your conference facilitator today for the Amgen Q3 2026 earnings conference call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session. To ask a question, please press star, then the number 1 on your telephone keypad. To withdraw your question, please press star one again. I would now like to introduce Casey Capparelli, Vice President of Investor Relations. Mr. Capparelli, you may now begin.
Thank you, Julianne. Good afternoon, everyone, and welcome to our third quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner, and Thomas Dittrich. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our safe harbor statement, and please note that actual results can vary materially.
Over to you, Bob. Good afternoon, and thank you for joining our call.
Our results through the first three quarters of the year reflect the strength of our business across a broad range of products and pipeline molecules. This is exactly the kind of performance our strategy was designed to achieve. Strong commercial and operations execution and continued innovation from our research and development organization reinforce our confidence in Amgen's ability to deliver durable long-term growth. For the latest quarter, total revenues grew a strong 8% year over year to $10.4 billion. Our six key growth drivers grew 27% year over year and represented over 70% of our third quarter product sales. Across the portfolio, 17 products delivered double-digit sales growth, and 17 products are now annualizing at more than $1 billion based on third quarter sales. We see significant opportunity to build on this momentum.
Many of our medicines address large, under-penetrated disease areas where the majority of patients remain untreated. Repatha, EVENITY, and TEZSPIRE are clear examples of that. Our strong financial performance gives us the flexibility to invest in innovation and the capabilities needed to support future growth while delivering attractive returns to shareholders. In the third quarter, we generated $3.7 billion in free cash flow, increased our investment in research and development by 11% year over year, and invested another $600 million in the business through capital expenditures. This was another productive quarter for our R&D organization. We reported positive phase III results from three important programs: IMDELLTRA in small cell lung cancer, where we are working to establish it as the cornerstone therapy, TEZSPIRE in eosinophilic esophagitis, an area with significant unmet need, and dazodalibep in Sjögren's disease, where no approved disease-modifying therapies currently exist.
I would note that each of these represents an established or potential first-in-class medicine with the opportunity to make a meaningful difference for patients while providing additional sources of long-term growth for Amgen. Likewise, our progress reflects the strength of our science and our commitment to pursuing novel approaches for serious diseases. That same focus guides our investment in programs such as MariTide, which is advancing through phase III development. Jay will discuss these programs and our other clinical advances in more detail shortly. We're also leveraging technology, data-driven insights, and artificial intelligence across Amgen to improve the speed and efficiency of how we discover, develop, manufacture, and deliver medicine to patients. We're encouraged by our performance this quarter, and our broad portfolio, continued investment in advancing pipeline give us confidence in Amgen's ability to deliver durable growth well into the next decade.
I want to thank our colleagues around the world for their dedication to our mission to serve patients and for the quality of their work every day. With that, I'll turn it over to Murdo.
Thanks, Bob. Looking back at the third quarter, what stands out for me is the remarkable progress we've made across our late-stage pipeline and broad in-line portfolio. We've seen important positive clinical readouts, regulatory milestones, and record sales performance for several of our key medicines. The consistency of these achievements reflects the breadth and strength of Amgen today and reinforces our confidence in the growth opportunities ahead. Our commercial performance reflects this progress. Product sales grew 8% year over year, and we have 17 products annualizing at more than $1 billion in sales. All six of our key growth drivers delivered double-digit growth in the quarter, together growing 27% year over year and now representing more than 70% of product sales. Starting with general medicine, Repatha delivered $1.1 billion in third quarter sales, growing 37% year over year.
Repatha's momentum continues to accelerate, with U.S. average weekly new-to-brand prescriptions increasing over 60% compared with the prior year. This growth is supported by increased urgency to treat in both secondary prevention and high-risk primary prevention patients. With the landmark VESALIUS-CV results, Repatha is now the only PCSK9 inhibitor with phase III cardiovascular outcomes evidence in both primary and secondary prevention. We're seeing deepening conviction and adoption among cardiologists and accelerating use in primary care. The updated ACC and AHA guidelines reinforce earlier, more intensive LDL cholesterol lowering and support the use of PCSK9 inhibitors without requiring prior treatment with ezetimibe. The new guidelines, supported by Repatha's differentiated outcomes data, strengthen clinical conviction that Repatha should be the first choice when additional LDL cholesterol lowering is needed beyond statins. This year alone, we expect more than 3 million additional patients globally to start treatment with Repatha.
With an estimated 100 million patients worldwide still above their LDL-C goals, we are only beginning to address the significant unmet need, giving us confidence in Repatha's growth potential into the 2030s. EVENITY sales increased 39% in the third quarter to $751 million, building on 38% year-over-year growth in the previous quarter. In the U.S., robust patient demand continues to drive momentum, supported by an expanding prescriber base and deeper adoption among treating physicians. We are increasing investment to expand our reach among physicians and to help more patients access treatment with EVENITY. The opportunity remains significant, particularly when we consider the devastating consequences of osteoporotic fractures. One in two patients who experience a hip fracture do not regain their pre-fracture mobility.
This reinforces the importance of earlier intervention and our conviction in EVENITY's potential to help more women at very high fracture risk, including those who have not yet experienced a fracture. In Japan, EVENITY maintains leadership in the bone builder category with nearly 60% volume share. Updated treatment guidelines and increasing use among treatment-naive patients are supporting continued growth and reinforcing EVENITY's important role in osteoporosis care. Moving to inflammation, TEZSPIRE sales grew 43% year over year, reaching $538 million, driven by strong demand in severe uncontrolled asthma. TEZSPIRE's growth continues to outperform the severe uncontrolled asthma market, with U.S. new-to-brand prescriptions growing 15% year over year versus 3% market growth. TEZSPIRE has achieved 34% new-to-brand prescription share among allergists in the U.S. and continues to gain share among pulmonologists, with substantial room for further adoption.
The consistent flow of strong clinical data continues to reinforce TEZSPIRE's differentiated efficacy across inflammatory diseases. Phase III results in chronic rhinosinusitis with nasal polyps demonstrated improvements in disease control and a reduction in the need for surgery. More recently, positive phase III results in eosinophilic esophagitis, or EoE, demonstrated meaningful improvements in key measures of disease activity and symptoms, highlighting another potential new opportunity for TEZSPIRE to help more patients. Turning to rare disease, this portfolio grew 21% year over year to $1.6 billion, reflecting continued momentum from additional indications and disciplined execution of international expansion. We see opportunity to extend the reach of these treatments, improve outcomes for patients, and sustain meaningful growth well into the next decade. UPLIZNA sales increased 191% year over year to $451 million in the third quarter, driven by strong patient demand across all approved indications.
UPLIZNA offers a highly differentiated clinical profile, combining outstanding efficacy that resonates with physicians and convenient twice-yearly dosing that benefits patients. This profile is supported by broad payer coverage and Amgen's comprehensive patient support services, helping physicians initiate treatment and support continuity of care. In the U.S., UPLIZNA is demonstrating significant growth in generalized myasthenia gravis, or gMG, with new and continuing patients increasing 45% quarter over quarter. Adoption is expanding among both biologic-naive patients and those transitioning from other therapies, reinforcing our confidence in UPLIZNA's potential to establish market leadership in this category. In IgG4-related disease, long-term follow-up data from the phase III MITIGATE study continued to reinforce UPLIZNA's durable efficacy profile. All patients who continued treatment with UPLIZNA remained flare-free through the first year of the open-label extension, with more than 70% achieving complete remission without glucocorticoids.
These durable results, together with growing disease awareness and improved diagnosis, support our confidence in UPLIZNA's potential to help many more patients. UPLIZNA continues to expand its reach internationally and is now launched in 25 markets outside the U.S. We see substantial opportunity for continued growth as we bring UPLIZNA to more patients around the world and advance its development across additional autoimmune diseases. TEPEZZA generated $526 million in third-quarter sales, a 6% decline year-over-year, impacted by an inventory build in the third quarter of last year. International adoption continues to build, with particularly encouraging uptake in Japan since entering the market last year. TEPEZZA has now launched in more than 20 countries worldwide, with three additional markets planned for the remainder of 2026. Our biosimilar portfolio delivered 26% year-over-year growth, generating $977 million in sales in the third quarter.
PAVBLU, our biosimilar to EYLEA, increased sales 41% year-over-year to $300 million in the quarter. Retina specialists recognize the benefits of PAVBLU's convenient prefilled syringe presentation, supported by Amgen's established capabilities in biosimilar manufacturing and supply. Our next wave of biosimilar candidates for EYLEA HD, OPDIVO, KEYTRUDA, and OCREVUS are in late-stage clinical development and represent large market opportunities. Turning to innovative oncology, the portfolio grew 21% year-over-year, generating $2.1 billion in sales in the third quarter. BLINCYTO sales increased 27% year-over-year to $496 million in the third quarter. This growth continues to reflect broad prescribing across academic and community settings and increasing international adoption. BLINCYTO's established role in treating B-cell acute lymphoblastic leukemia demonstrates the strength of our bispecific T-cell engager platform and its ability to deliver meaningful outcomes across different cancers. IMDELLTRA sales more than doubled year-over-year to $406 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
